Industry News
- Republicans press Becerra on gender-affirming care, reproductive rights
- FDA finalizes guidance allowing some contact lens sponsors 510(k) predicate leeway
- Recon: Novartis, Bicycle ink deal valued up to $1.7B to develop targeted radiotherapies; WHO revises COVID-19 vaccine recommendations for Omicron
- Focus Covid booster campaigns on high-risk people, WHO’s vaccine experts recommend
- Outdated perceptions of parenthood and surgery do not belong in 2023
- STAT+: Oscar Health names former Aetna executive as new CEO
- Positive topline results in trial for patients with early breast cancer
- A call for natural experiment guidance for planetary health
- DARWIN EU® has completed its first studies and is calling for new data partners
- Podcast Special: J&J's Andrie Leday Addresses ASC Market With Customized Approach
- Opinion/decision on a Paediatric investigation plan (PIP): Verquvo,Vericiguat, decision type: , therapeutic area: , PIP number: P/0476/2021
- George Watt Cardno
- Opinion/decision on a Paediatric investigation plan (PIP): Aimovig,erenumab, decision type: , therapeutic area: , PIP number: P/0475/2021
- Opinion/decision on a Paediatric investigation plan (PIP): Besponsa,inotuzumab ozogamicin, decision type: , therapeutic area: , PIP number: P/0478/2021
- Opinion/decision on a Paediatric investigation plan (PIP): Cresemba,Isavuconazonium sulfate, decision type: , therapeutic area: , PIP number: P/0479/2021